Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Xenon Pharmaceuticals Inc. Stories

2014-03-26 08:28:26

VANCOUVER, British Columbia, March 26, 2014 /PRNewswire/ -- Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive...

2013-09-10 08:28:54

VANCOUVER, British Columbia, Sept. 10, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce the appointment of Mr. Ian C. Mortimer as Chief Financial Officer. "We are delighted to welcome Ian to the Xenon team," said Dr. Simon Pimstone, Xenon's President and CEO. "Ian brings a combination of strong financial and operations experience that is highly relevant to Xenon. Given our pipeline of approved, development stage and discovery stage products and programs,...

2013-06-10 08:29:22

CARLSBAD, Calif. and VANCOUVER, British Columbia, June 10, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. announced today that Xenon has exercised its option to an exclusive worldwide license to XEN701, an antisense drug discovered in a collaboration between Isis and Xenon. For the license of XEN701, Isis earns a $2 million payment from Xenon. XEN701 is a drug candidate designed to inhibit the production of hepcidin, a target Xenon identified...

2013-04-22 08:28:21

VANCOUVER, British Columbia, April 22, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013. The prestigious Gold Leaf Awards ceremony will take place on Tuesday, April 23 at the BIO International Convention in Chicago. Several thousand guests will be in attendance, representing the global life sciences community. "We are honored to be recognized by our national industry peers in this...

2013-04-17 08:28:40

VANCOUVER, British Columbia, April 17, 2013 /PRNewswire/ -- Xenon announced that Merck, known as MSD outside the United States and Canada, through an affiliate, has exercised its option to exclusively license small molecule compounds for a novel target for the potential treatment of cardiovascular disease. In 2009, Xenon and Merck entered into a strategic alliance where Xenon employed its human clinical genetics platform to validate novel cardiovascular targets and collaborated on the...

2013-04-08 08:29:26

VANCOUVER, Canada, April 8, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award for 2013. (Photo: http://photos.prnewswire.com/prnh/20130408/SF89970) The LifeSciences British Columbia Awards took take place on Thursday, April 4 at the Vancouver Convention Centre with several hundred guests representing the British Columbia life sciences community. "We are honored to be...

2013-02-13 08:26:53

VANCOUVER, British Columbia, Feb. 13, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce the appointment of Gary J. Bridger PhD as Executive Vice President, Research and Development. "We are delighted to welcome Gary to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "As a co-founder and CSO of AnorMED, he was responsible for the development of MOZOBIL, a hematopoietic stem cell mobilizing agent for non-Hodgkin's lymphoma and multiple...

2013-02-05 08:33:29

VANCOUVER, British Columbia, Feb. 5, 2013 /PRNewswire/ -- Xenon, a clinical stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced that it has received a milestone payment from uniQure BV for the European Commission marketing approval of Glybera®, a novel gene therapy treatment for the orphan disease lipoprotein lipase deficiency (LPLD), and the first gene therapy approved in the Western world. Xenon exclusively licensed to uniQure BV its rights...

2011-05-02 05:00:00

VANCOUVER, British Columbia, May 2, 2011 /PRNewswire/ -- Xenon Pharmaceuticals Inc. (Xenon) announced today that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with Post Herpetic Neuralgia (PHN). Xenon is developing XEN402 as a topical treatment for a variety of painful disorders including PHN, as it specifically targets sodium channels such as Nav1.7. Sodium channels are highly expressed in sensory nerve endings and can be...

2011-03-23 05:00:00

VANCOUVER, British Columbia, March 23, 2011 /PRNewswire/ -- Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada. The Wightman Award is another major honour for Dr. Hayden, having previously been awarded the Order of Canada and Order of British Columbia, the Canadian Institutes of Health Research's Health Researcher of the Year Award, LifeSciences BC's Genome BC Award for Scientific...